PDF: IMPROVE-IT
(2015)Objective
Evaluate whether ezetimibe added to statin therapy reduces cardiovascular events in patients after recent ACS with guideline-level LDL.
Study Summary
• In patients stabilized after acute coronary syndrome, adding ezetimibe to simvastatin significantly reduced cardiovascular events compared to simvastatin alone. The benefit emerged after 1 year and was consistent across subgroups, including elderly and diabetic patients.
Intervention
Simvastatin 40 mg + ezetimibe 10 mg daily vs. simvastatin 40 mg + placebo. 18,144 patients with recent ACS (≤10 days) and LDL 50–100 mg/dL (on therapy) or 50–125 mg/dL (not on therapy). Median follow-up 6 years.
Study Design
Arms: Array
Outcome
• Primary: CV death, MI, unstable angina, revascularization ≥30 days, or stroke — 32.7% vs. 34.7%; HR 0.936 (95% CI 0.89–0.99); p=0.016
• CV death/MI/stroke — 20.4% vs. 22.2%; HR 0.90; p=0.003
• MI — 13.1% vs. 14.8%; HR 0.87; p=0.002
• Ischemic stroke — 3.4% vs. 4.1%; HR 0.79; p=0.008
• Hemorrhagic stroke — 0.8% vs. 0.6%; HR 1.38; p=0.11
• Urgent revascularization — 7.0% vs. 8.6%; HR 0.81; p=0.001
• No difference in CV death or all-cause mortality
• Adverse events: Similar rates of liver enzyme elevation, muscle events, cancer, and gallbladder-related events
• CV death/MI/stroke — 20.4% vs. 22.2%; HR 0.90; p=0.003
• MI — 13.1% vs. 14.8%; HR 0.87; p=0.002
• Ischemic stroke — 3.4% vs. 4.1%; HR 0.79; p=0.008
• Hemorrhagic stroke — 0.8% vs. 0.6%; HR 1.38; p=0.11
• Urgent revascularization — 7.0% vs. 8.6%; HR 0.81; p=0.001
• No difference in CV death or all-cause mortality
• Adverse events: Similar rates of liver enzyme elevation, muscle events, cancer, and gallbladder-related events
Bottom Line
Adding ezetimibe to simvastatin significantly reduced cardiovascular events in post-ACS patients with modest LDL-C lowering benefit.
Major Points
- IMPROVE-IT was the first trial to demonstrate that adding a non-statin LDL-lowering agent (ezetimibe) to statin therapy produces incremental cardiovascular benefit — settling a decade-long debate about whether LDL lowering per se (regardless of mechanism) reduces events ('LDL hypothesis').
- 18,144 patients stabilized after acute coronary syndrome — the largest and longest lipid-lowering trial post-ACS. Median follow-up of 6 years (some patients followed up to 9 years), providing robust long-term safety and efficacy data.
- LDL-C reduced from baseline ~95 mg/dL to 53.7 mg/dL with simvastatin+ezetimibe vs 69.5 mg/dL with simvastatin alone — a 24% further reduction. Established that LDL 50–55 mg/dL is safe and beneficial, paving the way for PCSK9 inhibitor trials targeting even lower LDL.
- Primary composite endpoint (CV death, MI, unstable angina requiring hospitalization, coronary revascularization ≥30 days, or nonfatal stroke): 32.7% vs 34.7% (HR 0.936, 95% CI 0.89–0.99, p=0.016) — modest but statistically significant 6.4% RRR.
- Stroke was significantly reduced: 4.1% vs 4.9% (HR 0.80, p=0.008) — a 20% relative reduction in stroke, the most robust individual endpoint, directly relevant to stroke prevention.
- No mortality benefit: all-cause death 15.3% vs 15.4% (HR 0.99, p=0.78), and CV death 6.8% vs 6.9% (HR 0.99, p=0.91) — the lack of mortality benefit despite reduced events was a key criticism.
- Validated the Cholesterol Treatment Trialists' (CTT) meta-regression: each 1 mmol/L (~39 mg/dL) LDL reduction yields ~22% relative risk reduction in MACE — IMPROVE-IT's 15.8 mg/dL further reduction predicted a ~9% RRR, and the observed 6.4% was within the expected range.
- Ezetimibe's mechanism (NPC1L1 intestinal cholesterol absorption inhibitor) is distinct from statins — proving that the pathway of LDL lowering matters less than the magnitude, and supporting combination therapy for patients not at goal on statins alone.
- Benefit was front-loaded: Kaplan-Meier curves separated early and continued to diverge through 7 years, with no plateau — suggesting sustained benefit with prolonged therapy, unlike some statin trials that showed early separation then parallel curves.
- Directly influenced 2018 AHA/ACC cholesterol guidelines, which for the first time recommended ezetimibe as a second-line agent for patients not at LDL goal on maximally tolerated statin — and the 2026 AHA dyslipidemia guidelines which further emphasized non-statin combination therapy.
Study Design
- Study Type
- Randomized, double-blind, placebo-controlled trial
- Randomization
- Yes
- Blinding
- Double-blind
- Sample Size
- 18144
- Follow-up
- Median 6 years
- Centers
- 1147
- Countries
- 39 countries
Primary Outcome
Definition: Composite of cardiovascular death, major coronary event, or nonfatal stroke
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| 34.7% | 32.7% | 0.936 (0.89–0.99) | 0.016 |
Limitations & Criticisms
- Modest absolute risk reduction (2.0% over 6 years, NNT ~50) — translates to treating 50 post-ACS patients with ezetimibe for 6 years to prevent one additional event. Cost-effectiveness has been debated, though generic ezetimibe availability has improved this.
- No mortality benefit whatsoever: all-cause death HR 0.99, CV death HR 0.99 — reducing nonfatal events without affecting mortality raises questions about the clinical meaningfulness of the benefit.
- Used moderate-intensity statin (simvastatin 40 mg) rather than high-intensity (atorvastatin 80 mg or rosuvastatin 40 mg) — the trial design predates 2013 guidelines recommending high-intensity statins for all post-ACS patients. Adding ezetimibe to a suboptimal statin regimen may overstate its benefit compared to simply intensifying statin therapy.
- Very long enrollment period (2005–2010) and follow-up (up to 9 years) — background therapy and practice patterns evolved substantially during the trial, with more patients on optimal medical therapy by trial's end.
- Simvastatin 80 mg arm was restricted mid-trial (2011 FDA safety communication) — some control-arm patients may have received suboptimal LDL lowering when they could have been up-titrated to 80 mg, artificially widening the LDL gap between arms.
- Industry-sponsored (Merck — manufacturer of both Vytorin and Zetia/ezetimibe) with industry involvement in study design and conduct. Earlier Merck controversy with ENHANCE trial (ezetimibe failed to reduce carotid intima-media thickness) cast a shadow over ezetimibe's credibility.
- Primary composite endpoint was broad (5 components including hospitalization for unstable angina and coronary revascularization) — the individual hard endpoints (CV death, MI) were not individually significant, raising questions about whether soft endpoints drove the composite result.
- No PCSK9 inhibitor comparator — by the time IMPROVE-IT reported (2015), PCSK9 inhibitors offered much larger LDL reductions (~60% vs 24%) and were entering clinical practice. IMPROVE-IT's modest ezetimibe effect was soon overshadowed.
- High discontinuation rate: ~42% of patients stopped study drug prematurely — diluting the observed treatment effect and raising generalizability concerns.
Citation
Cannon CP, et al. N Engl J Med. 2015;372:2387–97.